Vaxxinity, Inc.|4Aug 29, 4:45 PM ET

Guirakhoo Farshad 4

4 · Vaxxinity, Inc. · Filed Aug 29, 2022

Form 4

Period: 2022-01-13

Chief Scientific Officer

Transactions

Exercise/Conversion
Class A common stock
2022-08-15$0.57/sh+26,005$14,823→ 66,005 total
Exercise/Conversion
Class A common stock
2022-01-13$0.57/sh+10,000$5,700→ 10,000 total
Exercise/Conversion
Class A common stock
2022-07-29$0.57/sh+20,000$11,400→ 40,000 total
Exercise/Conversion
Class A common stock
2022-08-22$0.57/sh+2,640$1,505→ 68,645 total
Exercise/Conversion
Stock option (right to buy)
2022-01-13−10,000→ 116,730 total
Exercise: $0.57From: 2021-06-05Exp: 2031-03-01→ Class A common stock (10,000 underlying)
Exercise/Conversion
Stock option (right to buy)
2022-08-22−2,640→ 58,085 total
Exercise: $0.57From: 2021-06-05Exp: 2031-03-01→ Class A common stock (2,640 underlying)
Exercise/Conversion
Stock option (right to buy)
2022-07-29−20,000→ 86,730 total
Exercise: $0.57From: 2021-06-05Exp: 2031-03-01→ Class A common stock (20,000 underlying)
Exercise/Conversion
Stock option (right to buy)
2022-08-15−26,005→ 60,725 total
Exercise: $0.57From: 2021-06-05Exp: 2031-03-01→ Class A common stock (26,005 underlying)

Footnotes (3)

[F1]The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 10,000 shares of Class A common stock after the transaction on May 3, 2022 but the Reporting Person then owned 20,000 shares of Class A common stock.
[F2]These options are subject to a four year time-based vesting schedule, with 25% vested on 6/5/2021 and the remainder vesting in equal installments each month during the remainder of the vesting period.
[F3]The Reporting Person's Form 4 filed on May 5, 2022 incorrectly reported that the Reporting Person owned 116,730 of these stock options after the transaction on May 3, 2022 but the Reporting Person then owned 106,730 of these stock options.

Documents

1 file